Mammogen

Mammogen is a private, pre-revenue diagnostics company founded in 2019 with the ambitious goal of transforming breast cancer care through early detection. Its core technology platform centers on analyzing circulating messenger RNA (mRNA) biomarkers from biofluids like blood and saliva to identify disease signatures much earlier than current methods allow. The company is preparing for an upcoming clinical trial and positions itself not just as a biotech firm but as a movement aiming to address the full spectrum of patient experience, from scientific innovation to emotional and social support. Mammogen operates as part of the IVBH corporate studio.

Platform for developing multi-gene expression signatures based on novel circulating messenger RNA (mRNA) biomarkers detectable in biofluids (e.g., blood, saliva) for early disease detection.

Mammogen competes in the rapidly evolving liquid biopsy for early cancer detection market, facing large players like Grail (Illumina) and Exact Sciences, which use DNA-based methods. Its differentiation lies in its specific breast cancer focus, mRNA technology, and strong patient-community messaging.